Litcius/Paper detail

Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial

Martina Oneko, Laura C. Steinhardt, Reuben Yego, Ryan E. Wiegand, Phillip A. Swanson, Natasha KC, Dorcas Akach, Tony Sang, Julie Gutman, Elizabeth L. Nzuu, Allan Dungani, B. Kim Lee Sim, Paul Ndaya Oloo, Kephas Otieno, Dennis K Bii, Peter F. Billingsley, Eric R. James, Simon Kariuki, Aaron M. Samuels, Said Jongo, Winnie Chebore, Salim Abdulla, Claudia Daubenberger, Maxmillian Mpina, David Styers, Gail E. Potter, Ginnie Abarbanell, Thomas L. Richie, Stephen L. Hoffman, Robert A. Seder

2021Nature Medicine103 citationsDOI

Topics & Concepts

TolerabilityMedicineMalariaMalaria vaccineImmunogenicityPlaceboPlasmodium falciparumVaccinationVaccine efficacyAdverse effectImmunologyClinical endpointImmunityRandomized controlled trialInternal medicineImmune systemPathologyAlternative medicineMalaria Research and ControlMosquito-borne diseases and controlTravel-related health issues
Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial | Litcius